Non-alcoholic fatty liver disease (NAFLD) - DiabetesontheNet

This site is intended for healthcare professionals only

Non-alcoholic fatty liver disease (NAFLD)

Filter:

Diabetes Distilled: Fib-4 – A diagnostic and prognostic marker for liver and cardiovascular events and mortality

Should sequential Fib-4 testing now be made part of ongoing care in people with obesity and/or type 2 diabetes?

Diabetes Distilled: Advances in NAFLD – is when we eat as important as what we eat?

The effects of food timing on NAFLD risk, and the therapeutic potential of intermittent fasting and time-restricted eating.

Making the greatest impact with the fewest resources in 2023

Pam Brown outlines her ambitions for diabetes care within her practice in 2023, inspired by the new ADA Standards of Care.

Conference over coffee: Insulin in practice, frailty and abnormal liver function tests

Short, sharp summaries of key topics from the Welsh PCDS conference.

Diabetes Distilled: The twincretin tirzepatide – a promising treatment for NAFLD

The dual GIP/GLP-1 receptor agonist halves liver fat content in people with type 2 diabetes and NAFLD.

Conference over coffee: NAFLD and NASH

From the 2022 Diabetes UK Professional Conference: A whistle-stop tour of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Conference over coffee: Obesity, low-carb diets and NAFLD

Short, sharp summaries of key topics from the Scottish PCDS conference. Can read in the time it takes to make a cup of coffee!

Interactive case study: Fatty liver disease and type 2 diabetes

A challenging scenario to improve your clinical knowledge and skills.

How to diagnose and manage NAFLD in diabetes

Key information for the diagnosis and management of this challenging condition

Service evaluation: A diabetes service in the non-alcoholic fatty liver disease and post-liver-transplant clinics

The liver unit at University Hospitals Birmingham NHS Foundation Trust has developed its non-alcoholic fatty liver disease and post-liver-transplant clinics and restructured them to include input from the diabetes team. This article explains the two clinics and the developments the team continue to make.

Glucagon-like peptide-1 receptor agonists: A better option for treating and preventing steatohepatitis?

Q&A: Diabetes and the liver

Non-alcoholic fatty liver disease and type 2 diabetes: An overview of the problem

Resources

For the latest news and articles

Sign up to all DiabetesontheNet journals

Follow us for all the latest news and updates in diabetes.

Resources

Journals

Useful information

© Copyright Omniamed Communications. All Rights Reserved
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom

;